SHOULD WE TREAT GRADE 1 HYPERTENSION?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Because of the strategy of early diagnosis of arterial hypertension (AH) the majority of patients with prescription of the antihypertensive therapy (AHT) have grade 1 hypertension (AH1). Accumulated scientific evidence on the efficacy and safety of AHT for AH1 is insufficient for introduction of the active therapy, and the balance of harms and benefits is not clear in relation to AHT for AH1. The development of the next generation Russian guidelines for AH management in application to AH1 should take into account the totality of the scientific evidence as well as the perspective of the introduction of the national drug provision scheme. The best way to do it is to introduce more accurate diagnostic criteria for AH1 and the recommendation not to initiate the drug AHT for AH1 in cases of Low cardiovascular risk.

Full Text

Restricted Access

About the authors

Valeriy Alekseevich Aksenov

Social Insurance Fund of the Russian Federation

Email: v_aksenov@bk.ru

Vasiliy Viktorovich Vlasov

National Research University «Higher School of Economics»

Email: vlassov@cochrane.ru

References

  1. World Bank, Dying too young: addressing premature mortality and ill health due to non-communicable diseases and injuries in the Russian Federation, 2005.
  2. Бойцов С.А. Механизмы снижения смертности от ишемической болезни сердца в разных странах мира. Профилактическая медицина. 2013;16(5):9-19. [Boytsov S.A. Mechanisms of reduction of mortality from coronary heart disease in different countries. Preventive medicine. 2013;16(5):9-19 (in Russian)]
  3. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J., Nilsson P.M., Ruilope L.M., Schmieder R.E., Sirnes P.A., Sleight P., Viigimaa M., Waeber B., Zannad F.; Task Force Members. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J. Hypertens. 2013;31(10):1925-38.
  4. Российские рекомендации (4-й пересмотр). Секция артериальной гипертонии Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертензии. М., 2010. [Russian recommendations (4th revision). The section of arterial hypertension of the all-Russian scientific society of cardiologists. Diagnosis and treatment of hypertension. M., 2010 (in Russian)]
  5. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34 [Internet]. London: Royal College of Physicians (UK); 2011 Aug. (NICE Clinical Guidelines, No. 127.) Available from: http://www.ncbi.nlm.nih.gov/books/NBK83274/
  6. Lubsen J., Tijssen J.G. Large trials with simple protocols: indications and contraindications. Control. Clin. Trials. 1989;10(4 Suppl):151S-160S.
  7. Kopelman R.I., Dzau V.J. Trends in the therapy for mild hypertension. A word of caution. Arch. Intern. Med. 1985;145(1):47-9.
  8. Тимофеева Т.Н., Шальнова С.А., Константинов В.В., Иванов В.М., Капустина А.В., Баланова Ю.А., Лельчук И.Н., Деев А.Д. Распространенность факторов, влияющих на прогноз больных артериальной гипертонией, и оценка общего сердечно-сосудистого риска. Кардиоваскулярная терапия и профилактика. 2005; 6(1): 15-24. [Timofeeva T.N., Shal'nova S.A., Konstantinov V.V., Ivanov V.M., Kapustin A.V., Belanova Y.A., Lelchook I.N., Deev A.D. the Prevalence of factors influencing the prognosis of patients with arterial hypertension and assessment of overall cardiovascular risk. Cardiovascular therapy and prevention (in Russian)]
  9. Diao D., Wright J.M., Cundiff D.K., Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane database. Syst. Rev. 2012;8:CD006742.
  10. Society of Actuaries. Blood Pressure Study 1939. New York, NY: Society of actuaries and association of life insurance medical directors; 1940.
  11. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13.
  12. Perry Jr H.M., Goldman A.I., Lavin M.A., et al. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Ann. N. Y. Acad. Sci. 1978; 304:267-92.
  13. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am. J. Med. 1980 ;69(5):725-32.
  14. The effect of treatment on mortality in "mild" hypertension: results of the hypertension detection and follow-up program. N. Engl. J. Med. 1982;307(16):976-80.
  15. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet. 1980;1(8181):1261-7.
  16. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br. Med. J. (Clin. Res. Ed). 1985;291(6488):97-104.
  17. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991 ;265(24):3255-64.
  18. Kostis J.B., Davis B.R., Cutler J., Grimm R.H., Berge K.G., Cohen J.D., Lacy C.R., Perry H.M., Blaufox M.D., Wassertheil-Smoller S., Black H.R., Schron E., Berkson D.M., Curb J.D., Smith W.M., McDonald R., Applegate W.B. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278(3):212-6.
  19. Neaton J.D., Grimm R.H., Prineas R.J., Stamler J., Grandits G.A., Elmer P.J., Cutler J.A., Flack J.M., Schoenberger J.A., McDonald R. Treatment of mild hypertension study. Final results. Treatment of mild hypertension study research group. JAMA. 1993; 270(6):713-24.
  20. Liu L., Zhang Y., Liu G., Li W., Zhang X., Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J. Hypertens. 2005;23(12):2157-72.
  21. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. Grassi G., Heagerty A.M., Kjeldsen S.E., Laurent S., Narkiewicz K., Ruilope L., Rynkiewicz A., Schmieder R.E., Boudier H.A., Zanchetti A., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Erdine S., Kiowski W., Agabiti-Rosei E., Ambrosioni E., Lindholm L.H., Viigimaa M., Adamopoulos S., Agabiti-Rosei E., Ambrosioni E., Bertomeu V., Clement D., Erdine S., Farsang C., Gaita D., Lip G., Mallion J.M., Manolis A.J., Nilsson P.M., O'Brien E., Ponikowski P., Redon J., Ruschitzka F., Tamargo J., van Zwieten P., Waeber B., Williams B; Management of arterial hypertension of the European society of hypertension; European society of cardiology. 2007 Guidelines for the management of arterial hypertension: The Task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur. Heart J. 2007;28(12):1462-536.
  22. Mancia G., Laurent S., Agabiti-Rosei E., Ambrosioni E., Burnier M., Caulfield M.J., Cifkova R., Clément D., Coca A., Dominiczak A., Erdine S., Fagard R., Farsang C., Grassi G., Haller H., Heagerty A., Kjeldsen S.E., Kiowski W., Mallion J.M., Manolis A., Narkiewicz K., Nilsson P., Olsen M.H., Rahn K.H., Redon J., Rodicio J., Ruilope L., Schmieder R.E., Struijker-Boudier H.A., Van Zwieten P.A., Viigimaa M., Zanchetti A. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. Blood Press. 2009;18(6):308-47.
  23. Neal B., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure lowering treatment trialists' collaboration. Lancet. 2000;356(9246):1955-64.
  24. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
  25. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404): 1419.
  26. Sundström J., Arima H., Jackson R., Turnbull F., Rahimi K., Chalmers J., Woodward M., Neal B. Effects of blood pressure reduction in mild hypertension: A systematic review and meta-analysis. Ann. Intern. Med. 2015:162(3):184-91.
  27. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., C. Albus, P. Benlian, G. Boysen, R. Cifkova, C. Deaton, S. Ebrahim, M. Fisher, G. Germano, R. Hobbs, A. Hoes, S. Karadeniz, A. Mezzani, E. Prescott, L. Ryden, M. Scherer, M. Syvänne, W.J.M. Scholte Op Reimer, C. Vrints, D. Wood, J.L. Zamorano,F. Zannad. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2012;33(13):1635-701
  28. Кардиоваскулярная профилактика. Национальные рекомендации. Кардиоваскулярная терапия и профилактика. 2011;10(6):54 с. [Cardiovascular prevention. National recommendations. Cardiovascular therapy and prevention. 2011 ;10(6):54 p. (in Russian)]
  29. James P.A., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J., Lackland D.T., LeFevre M.L., MacKenzie T.D., Ogedegbe O., Smith S.C. Jr, Svetkey L.P., Taler S.J., Townsend R.R., Wright J.T. Jr, Narva A.S., Ortiz E. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint national committee (JNC 8). JAMA. 2014;311(5):507-20.
  30. Brindle P., Beswick A., Fahey T., Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92(12):1752-9.
  31. Mayor S. Hypertension diagnosis should be based on ambulatory blood pressure monitoring, NICE recommends. BMJ. 2011 ;343:d5421 doi: 10.1136/bmj.d5421
  32. Hodgkinson J., Mant J., Martin U., Guo B., Hobbs F.D.R., Deeks J.J., Heneghan C., Roberts N., McManus R.J. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ. 2011 ;342:d3621.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies